Skip to main content
Top
Published in: Indian Journal of Hematology and Blood Transfusion 3/2021

01-07-2021 | Lymphoma | Images

Chromosome 7q31 Amplification in Fluorescence In-Situ Hybridization: A Hallmark of Hepatosplenic Gamma Delta T Cell Lymphoma

Authors: Alpeshkumar Bipinbhai Kapadia, Shano Naseem, Man Updesh Singh Sachdeva, Sreejesh Sreedharanunni

Published in: Indian Journal of Hematology and Blood Transfusion | Issue 3/2021

Login to get access

Excerpt

A 16-year-female presented with history of irregular fever of five-month duration and left upper quadrant pain. She had moderate pallor, mild hepatomegaly and massive splenomegaly. Hemogram showed pancytopenia (hemoglobin-71 gm/L, total leucocyte count-2.0 × 109/L and platelet count-34 × 109/L). Peripheral blood film showed normal differential leukocyte counts with presence of nucleated red cells. Clinical, bone marrow (Fig. 1a–c), immunophenotypic findings (Fig. 1d–i) and T cell receptor gamma gene re-arrangement assay (Fig. 2a) were consistent with a diagnosis of hepatosplenic T cell lymphoma of gamma-delta T cell receptor type (γδHSTL). Fluorescence in-situ hybridization (FISH) testing showed 5–7 copies of 7q31 and two copies of centromere 7 consistent with amplification of 7q31 locus (Fig. 2b). Patient received 3 cycles of CHOP (Cyclophosphamide, Doxorubicin, Vincristine and Prednisolone) therapy till last follow up. Patient responded well with improvement in symptoms and hemogram findings (hemoglobin-139 g/L, leukocyte count-6.5 × 109/L and platelet count-83.0 × 109/L). Amplification of 7q22-q31 results from either isochromosome 7q [(i7)(q10)] or ring 7 (r7) [1]; and results in not only the gain of several putative cancer genes in 7q22-31 region, but also loss of genes in 7p favouring tumour growth [2]. While, (i7)(q10) and r(7) are hall mark findings identified by karyotyping in γδHSTL, the demonstration of amplification of 7q31 by a dual-colour FISH is an alternative cost-effective method to establish the diagnosis in patients with a diagnostic dilemma with closely related differential diagnoses including T-lineage acute lymphoblastic leukaemia-γδ type.
Literature
1.
go back to reference Tamaska J, Adam E, Kozma A, Gopcsa L, Andrikovics H, Tordai A et al (2006) Hepatosplenic gamma delta T-cell lymphoma with ring chromosome 7, an isochromosome 7q equivalent clonal chromosomal aberration. Virchows Arch Int J Pathol 449(4):479–483CrossRef Tamaska J, Adam E, Kozma A, Gopcsa L, Andrikovics H, Tordai A et al (2006) Hepatosplenic gamma delta T-cell lymphoma with ring chromosome 7, an isochromosome 7q equivalent clonal chromosomal aberration. Virchows Arch Int J Pathol 449(4):479–483CrossRef
2.
go back to reference Ferreiro JF, Rouhigharabaei L, Urbankova H, van der Krogt J-A, Michaux L, Shetty S et al (2014) Integrative genomic and transcriptomic analysis identified candidate genes implicated in the pathogenesis of hepatosplenic T-Cell lymphoma. PLoS One 9(7):e102977CrossRef Ferreiro JF, Rouhigharabaei L, Urbankova H, van der Krogt J-A, Michaux L, Shetty S et al (2014) Integrative genomic and transcriptomic analysis identified candidate genes implicated in the pathogenesis of hepatosplenic T-Cell lymphoma. PLoS One 9(7):e102977CrossRef
Metadata
Title
Chromosome 7q31 Amplification in Fluorescence In-Situ Hybridization: A Hallmark of Hepatosplenic Gamma Delta T Cell Lymphoma
Authors
Alpeshkumar Bipinbhai Kapadia
Shano Naseem
Man Updesh Singh Sachdeva
Sreejesh Sreedharanunni
Publication date
01-07-2021
Publisher
Springer India
Keyword
Lymphoma
Published in
Indian Journal of Hematology and Blood Transfusion / Issue 3/2021
Print ISSN: 0971-4502
Electronic ISSN: 0974-0449
DOI
https://doi.org/10.1007/s12288-020-01380-y

Other articles of this Issue 3/2021

Indian Journal of Hematology and Blood Transfusion 3/2021 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine